

Topical Collection

Chirality in Drugs and Drug Candidates

Message from the Collection Editors

This Topical Collection invites critical reviews, original research articles and other formats with comprehensive theoretical and experimental details focused on all aspects of chirality involved in drugs and drug candidates. This Topical Collection has the broad goal of illustrating recent and future trends in the development of successful chiral drugs and the search for new promising chiral drug candidates. Topics include the discovery, design and development of new chiral leads as well as synthetic and natural chiral drugs; chiral recognition studies; enantioselective synthesis; enantiomeric resolution; chiral drug analysis; stereochemical elucidation; and enantioselective studies on drug and drug candidate pharmacodynamics, pharmacokinetics, toxicity, and environment.

Collection Editors

Dr. Carla Fernandes

1. Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal
2. Centro Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR/CIMAR), Universidade do Porto, Edifício do Terminal de Cruzeiros do Porto de Leixões, Av. General Norton de Matos s/n, 4050-208 Matosinhos, Portugal

Dr. Maria Emília De Sousa

1. Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), 4450-208 Porto, Portugal
 2. Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
-



Drugs and Drug Candidates

an Open Access Journal
by MDPI



mdpi.com/si/139540

Drugs and Drug Candidates
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
ddc@mdpi.com

mdpi.com/journal/

[ddc](#)





Drugs and Drug Candidates

an Open Access Journal
by MDPI



[mdpi.com/journal/
ddc](https://mdpi.com/journal/ddc)



About the Journal

Message from the Editor-in-Chief

Drugs and Drug Candidates is an open access initiative of MDPI (Basel, Switzerland). Do you wish to share your knowledge on marketed or newly approved drugs for human or veterinary use? Do you wish to disseminate your recent results on the search for novel promising drug candidates? Our journal, animated by a young and dynamic team, is the ideal platform! Your submission, carefully followed by an academic editor, will be peer-reviewed by experts in the field of the work and a first decision will be notified within no more than two weeks. Involved in drug design, drug synthesis, drug evaluation, or drug market, *Drugs and Drug Candidates* is of worthy recognition and value.

I look forward to handling your contributions in the very near future. Should you need any information, do not hesitate to contact us.

Editor-in-Chief

Dr. Jean Jacques Vanden Eynde

Formerly Head, Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15 days after submission; acceptance to publication is undertaken in 4.7 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.